Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.66 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.43 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | STK32B | Q9NY57 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.42 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30773469 | 1.00 | NUDT1 (0.66) | NUDT1CDK5CDK5R1DYRK1APIM1 | |
| Oxazole SCHEMBL27757679 | 0.86 | NUDT1 (0.50) | NUDT1CDK5CDK5R1DYRK1APIM1 | |
| SCHEMBL30413155 | 0.80 | NUDT1 (1.00) | NUDT1CDK5CDK5R1DYRK1APIM1 | |
| SCHEMBL42319 | 0.80 | NUDT1 (1.00) | NUDT1CDK5CDK5R1DYRK1APIM1 | |
| Ammonia Solution, Strong SCHEMBL25287071 | 0.78 | NUDT1 (0.96) | NUDT1CDK5CDK5R1DYRK1APIM1 | |
| SCHEMBL31042611 | 0.78 | NUDT1 (0.96) | NUDT1CDK5CDK5R1DYRK1APIM1 | |
| Water SCHEMBL31266989 | 0.78 | NUDT1 (0.96) | NUDT1CDK5CDK5R1DYRK1APIM1 | |
| Water SCHEMBL30578580 | 0.78 | NUDT1 (0.96) | NUDT1CDK5CDK5R1DYRK1APIM1 | |
| SCHEMBL10653918 | 0.75 | ALDH1A1 (0.55) | NUDT1DYRK1APIM1BMPR1BPIK3C2G | |
| SCHEMBL28342822 | 0.75 | NUDT1 (0.46) | NUDT1DYRK1APIM1BMPR1BPIK3C2G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218521-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2023-07-13 | — | — | US | claimed |
| US-20200397695-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2020-12-24 | — | — | US | claimed |
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | claimed |
| EP-3532505-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | Urogen Pharma Ltd. (IL) | 2019-09-04 | — | — | EP | claimed |
| US-20190201334-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2019-07-04 | — | — | US | claimed |
| US-20190083592-A1 | IMMUNOSTIMULATORY COMBINATIONS | DARTMOUTH COLLEGE (US) | 2019-03-21 | — | — | US | claimed |
| US-20180186792-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2018-07-05 | — | — | US | claimed |
| WO-2018078620-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2018-05-03 | — | — | WO | claimed |
| US-9902724-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-02-27 | — | — | US | claimed |
| EP-1729768-B1 | IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS | MEDA AB (SE) | 2018-01-10 | — | — | EP | claimed |
| US-20040141950-A1 | Immunostimulatory combinations | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040091491-A1 | Immunostimulatory compositions and methods of stimulating an immune response | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-13 | — | — | US | claimed |
| WO-2004032829-A2 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF STIMULATING AN IMMUNE RESPONSE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-04-22 | — | — | WO | claimed |
| US-6706728-B2 | TOPICAL CERVIX IMMUNE RESPONSE MODIFIERS OF IMIDAZOQUINOLINE AMINES, IMIDAZOPYRIDINE AMINES, IMIDAZONAPHTHYRIDINE AMINES, OXAZOLOQUINOLINE AMINES, AND THIAZOLOQUINOLINE AMINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-03-16 | — | — | US | claimed |
| US-20040014779-A1 | Methods and compositions related to IRM compounds and toll-like recptor pathways | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-22 | — | — | US | claimed |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-23 | — | — | US | claimed |
| WO-2003072026-A2 | METHOD OF REDUCING AND TREATING UVB-INDUCED IMMUNOSUPPRESSION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-20030161797-A1 | Method of reducing and treating UVB-induced immunosuppression | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | claimed |
| WO-2003045391-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003043572-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091491-A1 | Immunostimulatory compositions and methods of stimulating an immune response | IFNG, MYD88, ICOS | NUDT1 3750/4885CDK5 4397/4885CDK5R1 3577/4885 |
| US-20230218521-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | IL2, CD47, IFNG | NUDT1 3813/4885CDK5 2295/4885CDK5R1 2684/4885 |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | ICOS, STAT6, INMT | NUDT1 1245/4885CDK5 1401/4885CDK5R1 1467/4885 |
| US-20190201334-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | IL2, CD47, IFNG | NUDT1 3813/4885CDK5 2295/4885CDK5R1 2684/4885 |
| US-20180186792-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | NUDT1 4229/4885CDK5 3293/4885CDK5R1 3121/4885 |
| US-20200397695-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | IL2, CD47, IFNG | NUDT1 3813/4885CDK5 2295/4885CDK5R1 2684/4885 |
| US-20040014779-A1 | Methods and compositions related to IRM compounds and toll-like recptor pathways | TLR4, TLR3, TLR6 | NUDT1 1145/4885CDK5 3156/4885CDK5R1 2318/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | NUDT1 3151/4885CDK5 2665/4885CDK5R1 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.